SCHEMBL30860896

SCHEMBL30860896

Cc1ccc(NC(=O)OC(C)(C)C)c2cnn(C3CCCCO3)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.39
CYP4A11 Q02928 2/20 0.39
ATR Q13535 3/20 0.38
MAPT P10636 2/20 0.36
TP53 P04637 1/20 0.36
LMNA P02545 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
RXRG P48443 1/20 0.35
RORC P51449 4/20 0.34
CYP3A4 P08684 2/20 0.33
DGAT1 O75907 1/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33
CYP2C19 P33261 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30860795 0.89 CYP4F2 (0.38) CYP4F2CYP4A11ATRRXRARXRB
SCHEMBL30860878 0.88 ATR (0.37) CYP4F2CYP4A11ATRTP53RXRA
SCHEMBL27228501 0.86 CYP4F2 (0.43) CYP4F2CYP4A11ATRLMNARXRA
SCHEMBL30860912 0.82 RXRA (0.41) CYP4F2CYP4A11ATRRXRARXRB
SCHEMBL30860940 0.80 RXRA (0.38) CYP4F2CYP4A11ATRTP53LMNA
SCHEMBL30797598 0.78 RXRA (0.39) CYP4F2CYP4A11ATRLMNARXRA
SCHEMBL27378131 0.78 RXRA (0.39) CYP4F2CYP4A11ATRLMNARXRA
SCHEMBL30797456 0.77 RXRA (0.38) CYP4F2CYP4A11ATRLMNARXRA
SCHEMBL27378150 0.77 RXRA (0.38) CYP4F2CYP4A11ATRLMNARXRA
SCHEMBL27378138 0.77 ALDH1A1 (0.38) CYP4F2CYP4A11ATRNPSR1RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174647-A1 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. 2024-05-30 US disclosed
WO-2024073073-A2 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2024-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174647-A1 KINASE MODULATORS AND METHODS OF USE THEREOF LRRK2, MAP3K20, MAP3K5 CYP4F2 4767/4885CYP4A11 4739/4885ATR 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.